SCHEMBL14802425

SCHEMBL14802425

CC(=O)N1CCN(c2ccc(C(=O)O)cc2)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 2/20 0.67
CASP6 P55212 1/20 0.67
MAPT P10636 6/20 0.61
KMT2A Q03164 2/20 0.61
MEN1 O00255 1/20 0.61
USP2 O75604 4/20 0.60
RAB9A P51151 2/20 0.60
NPC1 O15118 1/20 0.60
ALDH1A1 P00352 3/20 0.58
CYP2C9 P11712 2/20 0.58
HPGD P15428 2/20 0.58
CYP2C19 P33261 2/20 0.58
KDM4E B2RXH2 1/20 0.57
MAPK1 P28482 3/20 0.56
HSD17B10 Q99714 2/20 0.56
TP53 P04637 1/20 0.56
ALOX12 P18054 2/20 0.55
GAA P10253 1/20 0.55
ALOX15 P16050 1/20 0.55
MYC P01106 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1483566 0.87 MAPT (0.71) GFERCASP6MAPTKMT2AMEN1
SCHEMBL23610369 0.87 KDM4E (0.71) MAPTKMT2AMEN1USP2RAB9A
SCHEMBL17737082 0.87 KDM4E (0.71) MAPTKMT2AMEN1USP2RAB9A
SCHEMBL335061 0.85 KDM4E (0.61) MAPTKMT2AMEN1USP2RAB9A
SCHEMBL4985313 0.84 GFER (0.70) GFERCASP6MAPTKMT2AMEN1
SCHEMBL10876210 0.84 GFER (0.65) GFERCASP6MAPTKMT2AMEN1
SCHEMBL4670098 0.83 USP2 (0.72) GFERCASP6MAPTKMT2AMEN1
SCHEMBL12306047 0.82 KDM4E (0.57) MAPTKMT2AMEN1USP2RAB9A
SCHEMBL63450 0.81 CHEK1 (0.70) GFERMAPTKMT2AUSP2RAB9A
SCHEMBL17573009 0.81 HSP90AA1 (0.54) KMT2AMEN1ALDH1A1HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181235-B2 Substituted pyridines for modulating the WNT signaling pathway NOVARTIS AG (CH) 2015-11-10 US disclosed
US-20130079328-A1 COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY NOVARTIS AG (CH) 2013-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079328-A1 COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY WNT3A, WNT1, WNT3 GFER 3347/4885CASP6 982/4885MAPT 3765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.